Advanced Cell Diagnostics

Provider of the most
sensitive and specific RNA
in situ hybridization technology
Banner Image


  Secondary Navigation


Interested in information on new applications, interesting publications, new probe lists, newsletters or case studies? Enter your email address below.

American Association for Cancer Research Annual Meeting | AACR 2014

April 05 - April 09, 2014 | San Diego Convention Center | San Diego CA Booth 247

RNAscope technology will be discussed in the following presentations:


Tue, Apr 8, 3:20 - 3:35 PM
MS.ET07.01. Novel Biologics as Targeted Cancer Therapy
4766 - Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC
Christoph A. Schatz1, Charlotte Kopitz1, Sabine Wittemer-Rump1, Anette Sommer1, Lars Lindbom2, Motonobu Osada3, Hiroshi Yamanouchi3, Hung Huynh4, Thomas Krahn5, Khusru Asadullah1. 1Bayer Pharma AG, Berlin, Germany; 2Bayer Pharma AG, Berlin, Sweden; 3Bayer Yakuhin, Ltd., Tokyo, Japan; 4NCCS, Singapore, Singapore; 5Bayer Pharma AG, Wuppertal, Germany

Poster Sessions:

Mon, Apr 7, 8:00 AM - 12:00 PM
PO.IM01.03. Inflammation and the Tumor Microenvironment
1648/2 - Interleukin-6 expression is restricted to the prostate stromal compartment and is not expressed by either primary or metastatic prostatic adenocarcinoma cells
Shu-Han Yu1, Qizhi Zheng1, Jun Luo2, Anne Macgregor-Das1, Emmanuel S. Antonarakis3, Angelo M. De Marzo1, Karen Sfanos1. 1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD;2Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD; 3Deparment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

Mon, Apr 7, 8:00 AM - 12:00 PM
PO.MCB13.02. MicroRNAs and Solid Tumors 2: Diagnostics/Prognostics
1498/26 - Long non-coding RNA in situ hybridization signal patterns correlate with breast tumor pathology
Zhouwei Zhang, Zhihua Peng, Daniel Olsen, James deKay, Donald L. Weaver, Mark F. Evans. Univ. of Vermont College of Medicine, Burlington, VT
PO.MCB13.02. MicroRNAs and Solid Tumors 2: Diagnostics/Prognostics

Mon, Apr 7, 1:00 - 5:00 PM
PO.CL11.06. Predictive Biomarkers 2
2840/21 - Evaluation of HER-2 RNA and protein levels in a large cohort of breast cancer specimens to support development of a diagnostic immunofluorescence assay quantified by AQUA® Technology
Jennifer Bordeaux1, Krupa Chandrasekaran1, Sue Beruti1, Mike Nerenberg1, Corinne Ramos2, David Rimm3, Jelveh Lameh1, Naveen Dakappagari1. 1Genoptix, Inc., a Novartis Company, Carlsbad, CA;2Theranostics Health, Rockville, MD;3Yale School of Medicine, New Haven, CT

Tue, Apr 8, 1:00 - 5:00 PM
PO.CL01.04. Next Generation Profiling, Clinical Therapeutics, and Survivorship Research

4665/11 - Quantitative in situ biomarker analysis via ultrasensitive RNA in situ hybridization and automated image analysis
Hongwei Wang1, Laurent Lessard2, Nan Su1, Yuling Luo1, Dave Hoon2, Xiao-Jun Ma1. 1Advanced Cell Diagnostics, Hayward, CA; 2John Wayne Cancer Institute at St-John's Medical Center, Santa Monica, CA

Tracker Pixel for Entry